CJC-1295 & Ipamorelin
A GHRH analogue and a selective GH secretagogue, frequently studied in combination for their synergistic effects on pulsatile growth hormone release.
Overview
CJC-1295 and Ipamorelin are two peptides that act through different but complementary mechanisms to influence growth hormone (GH) release. They have been widely studied both individually and in combination, making them among the most referenced peptides in GH secretagogue research.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of GHRH with amino acid substitutions to improve stability. It is available in two forms: with DAC (Drug Affinity Complex) and without DAC (also known as Modified GRF 1-29 or Mod GRF).
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue, binding to the ghrelin/GHS receptor. Unlike earlier GH secretagogues such as GHRP-6, Ipamorelin has been noted for its selectivity in stimulating GH release without significantly affecting cortisol or prolactin levels in preclinical studies.
Molecular Profiles
CJC-1295 (no DAC / Mod GRF 1-29)
CJC-1295 (with DAC)
Ipamorelin
Mechanism of Action
The combination of CJC-1295 and Ipamorelin targets two distinct pathways in GH regulation:
- GHRH pathway (CJC-1295): CJC-1295 binds to the GHRH receptor on anterior pituitary somatotroph cells, stimulating GH synthesis and release. The no-DAC version mimics the natural pulsatile pattern of GHRH, while the DAC version provides sustained receptor activation.
- Ghrelin/GHS pathway (Ipamorelin): Ipamorelin binds to the growth hormone secretagogue receptor (GHS-R1a), which is the same receptor targeted by ghrelin. This amplifies GH release through a mechanism complementary to GHRH stimulation.
- Synergistic effect: Research has demonstrated that simultaneous activation of both the GHRH and GHS pathways produces a greater GH response than either pathway alone. This synergy is the primary rationale for studying these peptides in combination (Bowers, 1998).
- Selectivity of Ipamorelin: Unlike GHRP-2 and GHRP-6, Ipamorelin does not significantly stimulate ACTH, cortisol, prolactin, or aldosterone release, making it one of the most selective GH secretagogues studied (Raun et al., 1998).
CJC-1295: With DAC vs Without DAC
| Property | Without DAC (Mod GRF) | With DAC |
|---|---|---|
| Half-life | ~30 minutes | ~8 days |
| GH release pattern | Pulsatile (natural) | Sustained elevation |
| Albumin binding | No | Yes (via MPA linker) |
| Research preference | Pulsatile GH studies | Sustained GH elevation studies |
Key Published Research
Ipamorelin, the first selective growth hormone secretagogue
Raun K, et al. European Journal of Endocrinology. 1998; 139(5):552-561
Landmark study establishing Ipamorelin's selectivity for GH release without affecting cortisol, prolactin, FSH, LH, or TSH levels.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295
Teichman SL, et al. Journal of Clinical Endocrinology & Metabolism. 2006; 91(3):799-805
Clinical study demonstrating CJC-1295 with DAC's ability to sustain GH and IGF-1 elevation for extended periods with a single administration.
Storage and Handling
Lyophilised (unreconstituted):Store at -20°C for long-term stability. Both CJC-1295 and Ipamorelin are stable at 2-8°C for shorter periods.
Reconstituted:Store at 2-8°C. Use within 28 days. Avoid repeated freeze-thaw cycles.
Blended products: Pre-blended CJC-1295 + Ipamorelin preparations follow the same storage guidelines as individual peptides.
Recommended solvent: Bacteriostatic water or sterile water for laboratory use.
Frequently Asked Questions
Why are CJC-1295 and Ipamorelin studied together?
They target different receptors in the GH axis. CJC-1295 acts on the GHRH receptor while Ipamorelin acts on the GHS receptor. Research has shown that activating both pathways simultaneously produces a synergistic GH response greater than either alone.
What is the difference between CJC-1295 with DAC and without DAC?
The DAC (Drug Affinity Complex) is a chemical modification that allows CJC-1295 to bind to serum albumin, extending its half-life from approximately 30 minutes to around 8 days. Without DAC (Mod GRF 1-29), the peptide mimics the natural pulsatile pattern of GHRH release.
What makes Ipamorelin different from other GH secretagogues?
Ipamorelin is considered the most selective GH secretagogue studied to date. Unlike GHRP-2 and GHRP-6, it does not cause significant increases in cortisol, prolactin, or other pituitary hormones, as demonstrated by Raun et al. (1998).
Disclaimer: This information is compiled from published peer-reviewed literature and is provided for educational and research reference purposes only. It does not constitute medical advice. All products sold by Enhanced Research Compounds are intended exclusively for in-vitro research and laboratory use. They are not therapeutic goods, are not listed on the ARTG, and are not approved for human or animal consumption.